Citations

Showing 10 of 108104 citations.

Intraoperative appearance of gonadal vein embolization coil
Griebel, Lauren , Knuttinen, Grace , Wasson, Megan , Wasson, Megan

Mayo Clinic

Journal of Osteopathic Medicine | March 25, 2022 | Volume: 122 | Issue: 8 | Pages: 439-440

10.1515/jom-2021-0221 | PMID 35334504 Get It

Large Hepatic Adenomas and Hepatic Adenomatosis: A Multicenter Study of Risk Factors, Interventions, and Complications
Lammert, Craig , Toal, Emily, Mathur, Karan, Khungar, Vandana , House, Michael G. , Roberts, Lewis R. , Reddy, K. Rajender , Chalasani, Naga , Roberts, Lewis R

Mayo Clinic

American Journal of Gastroenterology | March 25, 2022 | Volume: 117 | Issue: 7 | Pages: 1089-1096

10.14309/ajg.0000000000001743 | PMID 35333776 Get It

INTRODUCTION: Beyond oral contraceptives (OCs), metabolic factors have been suggested to increase the risk of hepatocellular adenoma (HCA). The impact of risks remains poorly defined, particularly among men and those with adenomatosis. Thus, we aimed to examine HCA clinical and outcome characteristics through a large multicenter cohort. METHODS: HCA diagnosis was made based on a combination of clinical, radiologic, and histologic criteria. Patient and clinical data including follow-up imaging, complications, and interventions were collected between 2004 and 2018 from 3 large academic centers. RESULTS: Among 187 patients (163 female and 24 male) with HCA, 75 had solitary HCA, 58 had multiple HCAs, and 54 had adenomatosis. Over a median follow-up of 3.3 years (quartile 1: 1.2, quartile 3: 8.8), 34 patients (18%) had radiologic interventions, 41 (21%) had surgical resections, 10 (5%) developed tumoral hemorrhage, and 1 had malignant transformation. OC and corticosteroid use were present in 70% and 16%, respectively. Obesity (51%), type 2 diabetes (24%), hypertension (42%), and hypertriglyceridemia (21%) were also common. Metabolic comorbidities were more common in patients with large HCAs and adenomatosis. Compared with women, men had less hepatic steatosis (4% vs 27%), smaller HCAs (2.3 cm vs 4.4 cm), and more corticosteroid use (38% vs 11%) ( P < 0.05 for all). With OC cessation, 69% had a decrease in size of HCA, but 25% eventually required advanced interventions. DISCUSSION: In this large HCA cohort, obesity and metabolic comorbidities were important risk factors associated with large HCAs and adenomatosis. Long-term adverse outcomes were infrequent, 5% had tumor hemorrhage, and 1 patient exhibited malignant transformation.
Acute-on-Chronic Liver Failure
Bajaj, Jasmohan S. , Kamath, Patrick S. , O’Leary, Jacqueline G. , Wong, Florence , Lai, Jennifer C.

Mayo Clinic

American Journal of Gastroenterology | March 25, 2022 | Volume: 117 | Issue: 6 | Pages: 831-834

10.14309/ajg.0000000000001748 | PMID 35333779 Get It

Delayed Signs and Symptoms of Extended Release Guanfacine Overdose in Two Adolescent Patients: Implications of Monitoring on the Psychiatry Unit
Mishra, Sanskriti , Shekunov, Julia , Derscheid, Della J. , Canterbury, Elizabeth, Leung, Jonathan G. , Canterbury, Elizabeth A, Leung, Jonathan G

Mayo Clinic

Case Reports in Psychiatry | March 25, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-6

10.1155/2022/2149301 | PMID 35371580 Get It

Guanfacine is a selective alpha-2a adrenoreceptor agonist that with overdose can cause symptoms ranging from mild sedation to coma, respiratory depression, hyporeflexia, hypotonia, bradycardia, and hypotension. Despite a well-defined and predictable toxidrome, variations can be seen based on multiple factors including age, quantity ingested, organ functions, coingestions, time since ingestion, and specific dosage form. Here, we describe two cases of delayed presentation of extended release guanfacine toxicity and highlight the variations encountered in the toxidrome presentation. These cases bring to attention the importance of maintaining a high suspicion for such atypical presentations, keeping in mind the limitations of managing these complications on an inpatient psychiatric unit.
Stent placement for transplant hepatic artery stenosis
Devcic, Zlatko , Paz‐Fumagalli, Ricardo , Lewis, Andrew R. , Desai, Kush

Mayo Clinic

No container title available | March 25, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1148/cases.20221048 Get It

Kaizen Process Improvement in Radiology: Primer for Creating a Culture of Continuous Quality Improvement
Flug, Jonathan A. , Stellmaker, Jessica A. , Sharpe, Richard E. , Jokerst, Clinton, Tollefson, Chris , Bowman, Andrew W. , Nordland, Michelle, Hannafin, Cathy L , Froemming, Adam T. , Jokerst, Clinton E , Tollefson, Chris D , Bowman, Andrew W , Flug, Jonathan A , Nordland, Michelle R.

Mayo Clinic

RadioGraphics | March 25, 2022 | Volume: 42 | Issue: 3 | Pages: 919-928

10.1148/rg.210086 | PMID 35333633 Get It

766 12-year Analysis of Gender Disparity in Authorship of Peer-Reviewed Burn and Wound Care Literature
Khan, Iman F. , Ketheeswaran, Suvethavarshini, Turker, Ismail, Alasgarov, Elvin, Wiley, Brea, Guliyeva, Günel , Turker, Ismail

Mayo Clinic

Journal of Burn Care & Research | March 25, 2022 | Volume: 43 | Issue: Supplement_1 | Pages: S190-S190

10.1093/jbcr/irac012.319 Get It

Abstract Introduction The importance of gender equity and gender representation in academic publications has long been emphasized in medicine. It has been established that women represent a smaller proportion of primary and senior authors in high-impact medical journals than men and that original research articles written by women as primary and senior authors are less frequently sited than those authored by men. Currently, there is limited data evaluating whether this gender bias is present in plastic surgery and burn publications. We used bibliometric analysis of original research publications to analyze gender bias against women in one burn journal. Methods Using the journal, Burns, we conducted a bibliometric analysis of research publications from 2009 to 2020. A gender determining application was used to characterize the gender of the first and senior author. Ratios of male:male, female:male, male:female, and female:female were obtained and analyzed. Results Of the 1677 publications included, 40% have female first authors and 25.5% had female senior authors. Male:male authorships had the highest number of publications. Female:female authorship had the lowest number of publications of all the other ratios from 2009-2012, however there was a steep increase in 2013 in which male:female authorship had the lowest number of publications. Male senior authorship was associated with 2.9-fold increase in male first authorship [OR=2.99(95% CI 2.39, 3.76); p &lt; 0.0001). Conclusions Female representation in senior authorship positions in burn and wound care publications is increasing, however is still far from reaching gender parity. By analyzing authorship ratios by gender, we recommend a new way to evaluate gender disparity in burn and wound care academia.
Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas
Nelson, Lauren Hassan, Yin, Jun , Asmus, Erik, Ryder, Mabel , Morris, John C. , Hilger, Crystal, Bible, Keith C. , Rao, Sarika , Hassan Nelson, Lauren, Fuentes-Bayne, Harry, Yin, Jun , Hilger, Crystal R, Rao, Sarika N , Ryder, Mabel , Nelson, Lauren Juliette Hassan, Fuentes, Harry E , Morris, John C, Chintakuntlawar, Ashish V.

Mayo Clinic

Journal of the Endocrine Society | March 25, 2022 | Volume: 6 | Issue: 5 | Pages: No page available

10.1210/jendso/bvac044 | PMID 35402763 Get It

Abstract Context Metastatic pheochromocytomas and paragangliomas (mPPGL) are rare vascular neuroendocrine tumors that highly express vascular growth factors. Systemic treatment options in cases of unresectable multisite disease are limited. Multikinase inhibitors that inhibit angiogenesis, such as lenvatinib, have proven effective in several other malignancies, and may be a viable option for mPPGL. Objective We aimed to evaluate the efficacy of lenvatinib as salvage therapy in mPPGLs. Methods This was a retrospective analysis of mPPGL patients ≥ 18 years of age who received lenvatinib from 2015 to 2020 at a tertiary referral center. Patients were started on lenvatinib 20 mg daily and dose was adjusted according to tolerance or disease progression. Results Eleven patients were included. Median treatment duration was 14.7 months (95% CI, 2.3-NE). Treatment was discontinued due to disease progression, adverse events, or death. Overall survival at 12 months was 80.8% (95% CI, 42.3-94.9%) but its median was not reached. Median progression-free survival was 14.7 months (95% CI, 1.7-NE). Among the 8 patients with measurable disease, overall response rate was 63%, as 5/8 experienced a partial response and 3/8 had stable disease. Worsening hypertension and anemia were the most common adverse events. Conclusion Lenvatinib may be a viable treatment option for mPPGL, although at the potential risk of worsening hypertension. Larger, multicenter studies are needed to better characterize treatment efficacy.
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
Bozhanova, Galabina, Hassan, Jehanne , Appleton, Lizzie, Jennings, Victoria A. , Foo, Shane , Hak, Charleen ML Chan Wah, Patin, Emmanuel C. , Crespo-Rodriguez, Eva, Baker, Gabby, Armstrong, E, Chiu, M. , Pandha, Hardev , Samson, Adel , Roulstone, Victoria , Vile, Richard G. , Errington‐Mais, Fiona , Pedersen, Malin , Harrington, Kevin J. , Ono, Masahiro , Melcher, Alan , Hak, Charleen Chan Wah , McLaughlin, Martin , Patin, Emmanuel C , Errington-Mais, Fiona , Pedersen, Malin , Harrington, Kevin , Melcher, Alan A , Chan Wah Hak, Charleen Ml , McLaughlin, Martin , Kyula, Joan

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 25, 2022 | Volume: 10 | Issue: 3 | Pages: e004410

10.1136/jitc-2021-004410 | PMID 35338089 Get It

Background Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology of combinations is needed to improve on the benefit of immune checkpoint inhibitors (ICI). Methods Using a BRAFV600E-driven murine melanoma model, we tested the immunogenicity of HSV/BRAFi in immunocompetent C57BL mice. In addition to standard FACS analysis, we used the ‘Timer of Cell Kinetics and Activity’ system, which can analyze the temporal dynamics of different T cell subsets. This immune data was used to inform the selection of ICI for triple combination therapy, the effects of which were then further characterized using transcriptomics. Results Adding BRAFi treatment to HSV improved anti-tumor effects in vivo but not in vitro. Immune characterization showed HSV or dual therapy led to fewer intratumoral Treg, although with a more activated phenotype, together with more effector CD8 +T cells. Tocky analysis further showed that HSV/BRAFi dual treatment reduced the Tocky signal (reflecting engagement with cognate antigen), in both Treg and conventional subsets of CD4+, but not in CD8 +cells. However, a higher percentage of Treg than of conventional CD4 +maintained frequent engagement with antigens on treatment, reflecting a predominance of suppressive over effector function within the CD4 +compartment. The only T cell subset which correlated with a reduction in tumor growth was within Tocky signal positive conventional CD4+, supporting their therapeutic role. Targeting CD25 high, antigen-engaged Treg with a depleting anti-CD25 ICI, achieved complete cures in 100% of mice with triple therapy. Transcriptomic analysis confirmed reduction in Foxp3 on addition of anti-CD25 to HSV/BRAFi, as well as increases in expression of genes reflecting interferon signaling and cytotoxic activity. Conclusions Combination HSV/BRAFi is an immunogenic therapy for BRAF mutant melanoma, but cannot fully control tumors. Dual therapy results in changes in T cell dynamics within tumors, with relatively maintained antigen signaling in Treg compared with conv CD4+. Antigen-engaged CD4 +effectors correlate with tumor growth control, and depletion of Treg by addition of an anti-CD25 ICI, releasing suppression of conventional CD4 +effectors by Treg, enhances survival and activates immune signaling within tumors.